

Frank Bretz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3357484/publications.pdf>

Version: 2024-02-01

166
papers

16,575
citations

76196

40
h-index

17055

122
g-index

180
all docs

180
docs citations

180
times ranked

23591
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 94-111.	0.6	9
2	Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 554-559.	0.6	3
3	Testing for similarity of binary efficacy-toxicity responses. <i>Biostatistics</i> , 2022, 23, 949-966.	0.9	2
4	Discussion on 'Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials'. <i>Biometrical Journal</i> , 2022, 64, 243-245.	0.6	3
5	Missing data imputation in clinical trials using recurrent neural network facilitated by clustering and oversampling. <i>Biometrical Journal</i> , 2022, 64, 863-882.	0.6	4
6	Estimands and Complex Innovative Designs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1183-1190.	2.3	10
7	Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures. <i>Pharmaceutical Statistics</i> , 2022, 21, 757-763.	0.7	0
8	Comparison of normal distribution-based and nonparametric decision limits on the GH2000 score for detecting growth hormone misuse (doping) in sport. <i>Biometrical Journal</i> , 2021, 63, 187-200.	0.6	4
9	Reference range: Which statistical intervals to use?. <i>Statistical Methods in Medical Research</i> , 2021, 30, 523-534.	0.7	14
10	Editorial: Roles of Hypothesis Testing, p-Values and Decision Making in Biopharmaceutical Research. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 1-5.	0.6	6
11	Estimands: What they are and why they are important for pharmacometricians. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 279-282.	1.3	6
12	Statistics in Biopharmaceutical Research Best Papers Award. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 129-130.	0.6	0
13	Simultaneous confidence tubes for comparing several multivariate linear regression models. <i>Biometrical Journal</i> , 2021, , .	0.6	1
14	Connecting Instrumental Variable methods for causal inference to the Estimand Framework. <i>Statistics in Medicine</i> , 2021, 40, 5605-5627.	0.8	7
15	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021, 40, 6235-6242.	0.8	5
16	Beyond Randomized Clinical Trials: Use of External Controls. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 806-816.	2.3	65
17	Equivalence of regression curves sharing common parameters. <i>Biometrics</i> , 2020, 76, 518-529.	0.8	6
18	Machine learning for clinical trials in the era of COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 506-517.	0.6	40

#	ARTICLE	IF	CITATIONS
19	Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 419-426.	0.6	26
20	Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 397-398.	0.6	5
21	Commentary on Parker and Weir. <i>Clinical Trials</i> , 2020, 17, 567-569.	0.7	14
22	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 461-477.	0.6	31
23	Graphical approaches for the control of generalized error rates. <i>Statistics in Medicine</i> , 2020, 39, 3135-3155.	0.8	1
24	Confidence Sets for Statistical Classification. <i>Stats</i> , 2019, 2, 332-346.	0.5	2
25	Quantitative approaches underpinning decision making. <i>Biometrical Journal</i> , 2019, 61, 1103-1103.	0.6	0
26	Symmetric graphs for equally weighted tests, with application to the Hochberg procedure. <i>Statistics in Medicine</i> , 2019, 38, 5268-5282.	0.8	5
27	Commentary on "Statistics at FDA: Reflections on the Past Six Years". <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 20-25.	0.6	2
28	Advanced Topics in Biostatistics: Editorial for the ISCB38 Special Issue. <i>Biometrical Journal</i> , 2019, 61, 243-244.	0.6	0
29	Confidence Sets for Statistical Classification (II): Exact Confidence Sets. <i>Stats</i> , 2019, 2, 439-446.	0.5	1
30	Replicability, Reproducibility, and Multiplicity in Drug Development. <i>Chance</i> , 2019, 32, 4-11.	0.1	8
31	Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	11
32	Equivalence of Regression Curves. <i>Journal of the American Statistical Association</i> , 2018, 113, 711-729.	1.8	29
33	Assessing the similarity of dose response and target doses in two non-overlapping subgroups. <i>Statistics in Medicine</i> , 2018, 37, 722-738.	0.8	12
34	Key Aspects of Modern, Quantitative Drug Development. <i>Statistics in Biosciences</i> , 2018, 10, 283-296.	0.6	3
35	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. <i>Statistics in Medicine</i> , 2018, 37, 3387-3402.	0.8	8
36	Computation of an exact confidence set for a maximum point of a univariate polynomial function in a given interval. <i>Statistics and Probability Letters</i> , 2017, 122, 157-161.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Multiple confidence intervals for selected parameters adjusted for the false coverage rate in monotone dose-response microarray experiments. <i>Biometrical Journal</i> , 2017, 59, 732-745.	0.6	4
38	Adaptive designs: The Swiss Army knife among clinical trial designs?. <i>Clinical Trials</i> , 2017, 14, 417-424.	0.7	10
39	Estimands and Their Role in Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 268-271.	0.6	45
40	Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials. <i>Statistics in Medicine</i> , 2017, 36, 1334-1360.	0.8	42
41	A unified framework for weighted parametric multiple test procedures. <i>Biometrical Journal</i> , 2017, 59, 918-931.	0.6	13
42	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014). <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 418-429.	1.3	52
43	Estimands: discussion points from the PSI estimands and sensitivity expert group. <i>Pharmaceutical Statistics</i> , 2017, 16, 6-11.	0.7	32
44	Estimands in clinical trials – broadening the perspective. <i>Statistics in Medicine</i> , 2017, 36, 5-19.	0.8	96
45	Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes. <i>Biometrika</i> , 2017, 104, 1003-1010.	1.3	7
46	The MCP-Mod Methodology: Practical Considerations and the DoseFinding R Package. , 2017, , 205-227.		2
47	Multiple Test Strategies for Comparing Several Doses with a Control in Confirmatory Trials. , 2017, , 279-290.		1
48	A simple and flexible graphical approach for adaptive group-sequential clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 202-216.	0.4	14
49	Bayesian Two-Stage Dose Finding for Cytostatic Agents Via Model Adaptation. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2016, 65, 465-482.	0.5	2
50	Simultaneous Confidence Tubes in Multivariate Linear Regression. <i>Scandinavian Journal of Statistics</i> , 2016, 43, 879-885.	0.9	3
51	Confidence Sets for Optimal Factor Levels of a Response Surface. <i>Biometrics</i> , 2016, 72, 1285-1293.	0.8	10
52	Model selection versus model averaging in dose finding studies. <i>Statistics in Medicine</i> , 2016, 35, 4021-4040.	0.8	37
53	Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. <i>Statistics in Medicine</i> , 2016, 35, 325-347.	0.8	166
54	Threshold-crossing: A Useful Way to Establish the Counterfactual in Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 699-712.	2.3	61

#	ARTICLE	IF	CITATIONS
55	Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials. <i>Statistics in Medicine</i> , 2016, 35, 5325-5337.	0.8	2
56	Authors' response to comments. <i>Statistics in Medicine</i> , 2016, 35, 364-367.	0.8	1
57	Statistical calibration and exact one-sided simultaneous tolerance intervals for polynomial regression. <i>Journal of Statistical Planning and Inference</i> , 2016, 168, 90-96.	0.4	10
58	Dose Response Signal Detection under Model Uncertainty. <i>Biometrics</i> , 2015, 71, 996-1008.	0.8	9
59	Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel. <i>Statistics in Medicine</i> , 2015, 34, 3461-3480.	0.8	6
60	Seventh international French Society of Statistics meeting on statistical methods in biopharmacy: emerging topics for statistical methodology in clinical drug development. <i>Statistics in Medicine</i> , 2015, 34, 2981-2982.	0.8	0
61	An Exact Confidence Set for a Maximum Point of a Univariate Polynomial Function in a Given Interval. <i>Technometrics</i> , 2015, 57, 559-565.	1.3	5
62	Normal probability plots with confidence. <i>Biometrical Journal</i> , 2015, 57, 52-63.	0.6	15
63	Designing dose-finding studies with an active control for exponential families. <i>Biometrika</i> , 2015, 102, 937-950.	1.3	3
64	Simultaneous confidence bands for a percentile line in linear regression. <i>Computational Statistics and Data Analysis</i> , 2015, 81, 1-9.	0.7	6
65	Advanced multiplicity adjustment methods in clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 693-713.	0.8	61
66	Optimal designs for dose finding studies with an active control. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2014, 76, 265-295.	1.1	8
67	Model-based dose finding under model uncertainty using general parametric models. <i>Statistics in Medicine</i> , 2014, 33, 1646-1661.	0.8	121
68	Multiplicity and replicability: two sides of the same coin. <i>Pharmaceutical Statistics</i> , 2014, 13, 343-344.	0.7	13
69	Some Practical Considerations for Phase III Studies With Biomarker Evaluations. <i>Journal of Clinical Oncology</i> , 2014, 32, 854-855.	0.8	5
70	Introduction to Multiple Test Problems, with Applications to Adaptive Designs. , 2014, , 337-348.		0
71	A note on testing families of hypotheses using graphical procedures. <i>Statistics in Medicine</i> , 2014, 33, 5340-5346.	0.8	6
72	Approaches for Optimal Dose Selection for Adaptive Design Trials. <i>Statistics in the Health Sciences</i> , 2014, , 125-137.	0.2	5

#	ARTICLE	IF	CITATIONS
73	The Need for and the Future of Adaptive Designs in Clinical Development. <i>Statistics in the Health Sciences</i> , 2014, , 3-23.	0.2	0
74	On the efficiency of two-stage response-adaptive designs. <i>Statistics in Medicine</i> , 2013, 32, 1646-1660.	0.8	18
75	Simultaneous inference for several quantiles of a normal population with applications. <i>Biometrical Journal</i> , 2013, 55, 360-369.	0.6	10
76	Directional Error Rates of Closed Testing Procedures. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 345-355.	0.6	3
77	Panel forum on multiple comparison procedures: A commentary from a complex trial design and analysis plan. <i>Biometrical Journal</i> , 2013, 55, 275-293.	0.6	5
78	Exact Simultaneous Confidence Bands for Quadratic and Cubic Polynomial Regression with Applications in Dose Response Study. <i>Australian and New Zealand Journal of Statistics</i> , 2013, 55, 421-434.	0.4	7
79	Author's reply. <i>Biometrical Journal</i> , 2013, 55, 266-266.	0.6	0
80	Memory and other properties of multiple test procedures generated by entangled graphs. <i>Statistics in Medicine</i> , 2013, 32, 1739-1753.	0.8	20
81	Multiple Testing in Group Sequential Trials Using Graphical Approaches. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 311-320.	0.6	81
82	Multiple Contrast Tests for Testing Dose-Response Relationships Under Order-Restricted Alternatives. , 2012, , 233-247.		1
83	Multiplicity in Clinical Trials. , 2012, , 889-896.		0
84	Multiple Hypotheses Testing Based on Ordered p -Values: A Historical Survey with Applications to Medical Research. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 595-609.	0.4	14
85	Simultaneous Confidence Bands for Nonlinear Regression Models with Application to Population Pharmacokinetic Analyses. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 708-725.	0.4	28
86	Response-adaptive dose-finding under model uncertainty. <i>Annals of Applied Statistics</i> , 2011, 5, .	0.5	34
87	Alterations of pre-mRNA splicing in human inflammatory bowel disease. <i>European Journal of Cell Biology</i> , 2011, 90, 603-611.	1.6	41
88	Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures. <i>Statistics in Medicine</i> , 2011, 30, 1489-1501.	0.8	45
89	Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. <i>Pharmaceutical Statistics</i> , 2011, 10, 96-104.	0.7	33
90	Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. <i>Biometrical Journal</i> , 2011, 53, 894-913.	0.6	123

#	ARTICLE	IF	CITATIONS
91	Multiple and Repeated Testing of Primary, Coprimary, and Secondary Hypotheses. <i>Statistics in Biopharmaceutical Research</i> , 2011, 3, 336-352.	0.6	22
92	Adaptive Trial Designs. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 109-130.	0.2	1
93	MCP2009 – 6 th International Conference on Multiple Comparison Procedures. <i>Biometrical Journal</i> , 2010, 52, 705-707.	0.6	1
94	Simultaneous confidence bands for all contrasts of three or more simple linear regression models over an interval. <i>Computational Statistics and Data Analysis</i> , 2010, 54, 1475-1483.	0.7	10
95	Sample size and proportion of Japanese patients in multi-regional trials. <i>Pharmaceutical Statistics</i> , 2010, 9, 207-216.	0.7	18
96	Hierarchical testing of multiple endpoints in group-sequential trials. <i>Statistics in Medicine</i> , 2010, 29, 219-228.	0.8	70
97	Practical considerations for optimal designs in clinical dose finding studies. <i>Statistics in Medicine</i> , 2010, 29, 731-742.	0.8	60
98	From Adaptive Design to Modern Protocol Design for Drug Development: Part I. Editorial and Summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum. <i>Drug Information Journal</i> , 2010, 44, 325-331.	0.5	9
99	Optimal designs for the emax, log-linear and exponential models. <i>Biometrika</i> , 2010, 97, 513-518.	1.3	43
100	A Simulation Study to Compare New Adaptive Dose-Ranging Designs. <i>Statistics in Biopharmaceutical Research</i> , 2010, 2, 487-512.	0.6	58
101	Data Monitoring in Adaptive Dose-Ranging Trials. <i>Statistics in Biopharmaceutical Research</i> , 2010, 2, 513-521.	0.6	8
102	Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies. <i>Statistics in Biopharmaceutical Research</i> , 2010, 2, 435-454.	0.6	40
103	Shortcuts for Locally Consonant Closed Test Procedures. <i>Journal of the American Statistical Association</i> , 2010, 105, 660-669.	1.8	25
104	Multiplicity in Clinical Trials. , 2010, , 889-896.		3
105	Adaptive Dose-Ranging Studies. , 2010, , 11-1-11-16.		1
106	Robustness considerations in selecting efficient two-color microarray designs. <i>Bioinformatics</i> , 2009, 25, 2355-2361.	1.8	11
107	Adaptivity in drug discovery and development. <i>Drug Development Research</i> , 2009, 70, 169-190.	1.4	22
108	Trimmed Weighted Simes' Test for Two One-Sided Hypotheses With Arbitrarily Correlated Test Statistics. <i>Biometrical Journal</i> , 2009, 51, 885-898.	0.6	8

#	ARTICLE	IF	CITATIONS
109	A graphical approach to sequentially rejective multiple test procedures. <i>Statistics in Medicine</i> , 2009, 28, 586-604.	0.8	311
110	Adaptive designs for confirmatory clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 1181-1217.	0.8	208
111	Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. <i>Statistics in Medicine</i> , 2009, 28, 1445-1463.	0.8	168
112	Assessing Nonsuperiority, Noninferiority, or Equivalence When Comparing Two Regression Models Over a Restricted Covariate Region. <i>Biometrics</i> , 2009, 65, 1279-1287.	0.8	40
113	Discussion of "Some Controversial Multiple Testing Problems in Regulatory Applications" by H. M. J. Hung and S.-J. Wang. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 25-34.	0.4	10
114	Computation of Multivariate Normal and t Probabilities. <i>Lecture Notes in Statistics</i> , 2009, , .	0.1	505
115	MCPMod : An R Package for the Design and Analysis of Dose-Finding Studies. <i>Journal of Statistical Software</i> , 2009, 29, .	1.8	55
116	Adaptive Dunnett tests for treatment selection. <i>Statistics in Medicine</i> , 2008, 27, 1612-1625.	0.8	89
117	Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests. <i>Statistics in Medicine</i> , 2008, 27, 4914-4927.	0.8	104
118	Aesthetics and Power Considerations in Multiple Testing " A Contradiction?. <i>Biometrical Journal</i> , 2008, 50, 657-666.	0.6	24
119	Simultaneous Inference in General Parametric Models. <i>Biometrical Journal</i> , 2008, 50, 346-363.	0.6	10,085
120	Dose Finding " A Challenge in Statistics. <i>Biometrical Journal</i> , 2008, 50, 480-504.	0.6	80
121	Multiple Comparison Procedures in Linear Models. , 2008, , 423-431.		10
122	Efficient and easy-to-use sample size formulas in ratio-based non-inferiority tests. <i>Journal of Applied Statistics</i> , 2008, 35, 893-900.	0.6	1
123	Optimal Designs for Dose-Finding Studies. <i>Journal of the American Statistical Association</i> , 2008, 103, 1225-1237.	1.8	96
124	Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2007, 17, 965-995.	0.4	174
125	Preface: <i>Biom. J.</i> 1/2007. <i>Biometrical Journal</i> , 2007, 49, 5-6.	0.6	6
126	Some new methods for the comparison of two linear regression models. <i>Journal of Statistical Planning and Inference</i> , 2007, 137, 57-67.	0.4	17

#	ARTICLE	IF	CITATIONS
127	Power and sample size when multiple endpoints are considered. <i>Pharmaceutical Statistics</i> , 2007, 6, 161-170.	0.7	90
128	Pooling batches in drug stability study by using constant-width simultaneous confidence bands. <i>Statistics in Medicine</i> , 2007, 26, 2759-2771.	0.8	22
129	Powerful short-cuts for multiple testing procedures with special reference to gatekeeping strategies. <i>Statistics in Medicine</i> , 2007, 26, 4063-4073.	0.8	69
130	Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. <i>Statistics in Medicine</i> , 2007, 26, 4925-4938.	0.8	44
131	Design and Analysis of Dose-Finding Studies Combining Multiple Comparisons and Modeling Procedures. <i>Journal of Biopharmaceutical Statistics</i> , 2006, 16, 639-656.	0.4	74
132	Adaptive Dose-Response Studies. <i>Drug Information Journal</i> , 2006, 40, 451-461.	0.5	50
133	Power and sample size computations in simultaneous tests for non-inferiority based on relative margins. <i>Statistics in Medicine</i> , 2006, 25, 1131-1147.	0.8	16
134	Efficient design and analysis of two colour factorial microarray experiments. <i>Computational Statistics and Data Analysis</i> , 2006, 50, 499-517.	0.7	29
135	An extension of the Williams trend test to general unbalanced linear models. <i>Computational Statistics and Data Analysis</i> , 2006, 50, 1735-1748.	0.7	53
136	Simultaneous confidence sets and confidence intervals for multiple ratios. <i>Journal of Statistical Planning and Inference</i> , 2006, 136, 2640-2658.	0.4	36
137	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations. <i>Biometrical Journal</i> , 2006, 48, 635-643.	0.6	101
138	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. <i>Biometrical Journal</i> , 2006, 48, 623-634.	0.6	235
139	Analysis of Dose-Response Studies Modeling Approaches. , 2006, , 146-171.		37
140	Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies. <i>Biometrics</i> , 2005, 61, 738-748.	0.8	305
141	Adaptive designs based on the truncated product method. <i>BMC Medical Research Methodology</i> , 2005, 5, 30.	1.4	7
142	Multiplicity issues in microarray experiments. <i>Methods of Information in Medicine</i> , 2005, 44, 431-7.	0.7	23
143	Simultaneous Tests and Confidence Intervals for the Evaluation of Agricultural Field Trials. <i>Agronomy Journal</i> , 2004, 96, 1323-1330.	0.9	4
144	MR imaging of lung parenchyma at 0.2T: evaluation of imaging techniques, comparative study with chest radiography and interobserver analysis. <i>European Radiology</i> , 2004, 14, 703-708.	2.3	19

#	ARTICLE	IF	CITATIONS
145	Assessment of Optimal Selected Prognostic Factors. <i>Biometrical Journal</i> , 2004, 46, 364-374.	0.6	101
146	Efficient two-sample designs for microarray experiments with biological replications. <i>In Silico Biology</i> , 2004, 4, 461-70.	0.4	10
147	Identifying effective and/or safe doses by stepwise confidence intervals for ratios. <i>Statistics in Medicine</i> , 2003, 22, 847-858.	0.8	29
148	Comparison of Exact and Resampling Based Multiple Testing Procedures. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2003, 32, 461-473.	0.6	4
149	Statistical Analysis of Monotone or Non-monotone Dose-Response Data from <i>In Vitro</i> Toxicological Assays. <i>ATLA Alternatives To Laboratory Animals</i> , 2003, 31, 81-96.	0.7	40
150	Dose-Response and Thresholds in Mutagenicity Studies: A Statistical Testing Approach. <i>ATLA Alternatives To Laboratory Animals</i> , 2003, 31, 97-103.	0.7	3
151	Comparison of Methods for the Computation of Multivariate Probabilities. <i>Journal of Computational and Graphical Statistics</i> , 2002, 11, 950-971.	0.9	266
152	Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data. <i>Statistics in Medicine</i> , 2002, 21, 3325-3335.	0.8	30
153	Critical point and power calculations for the studentized range test for generally correlated means. <i>Journal of Statistical Computation and Simulation</i> , 2001, 71, 85-97.	0.7	4
154	Nonparametric All-Pairs Multiple Comparisons. <i>Biometrical Journal</i> , 2001, 43, 571-580.	0.6	47
155	On the Numerical Availability of Multiple Comparison Procedures. <i>Biometrical Journal</i> , 2001, 43, 645-656.	0.6	84
156	Obtaining Critical Values for Simultaneous Confidence Intervals and Multiple Testing. <i>Biometrical Journal</i> , 2001, 43, 657-663.	0.6	2
157	The distribution of extra-pair young within and among broods - a technique to calculate deviations from randomness. <i>Journal of Avian Biology</i> , 2001, 32, 358-363.	0.6	16
158	TESTING DOSE-RESPONSE RELATIONSHIPS WITH A PRIORI UNKNOWN, POSSIBLY NONMONOTONE SHAPES. <i>Journal of Biopharmaceutical Statistics</i> , 2001, 11, 193-207.	0.4	26
159	Evaluation of Animal Carcinogenicity Studies: Cochran-Armitage Trend Test vs. Multiple Contrast Tests. <i>Biometrical Journal</i> , 2000, 42, 553-567.	0.6	25
160	One-sided Simultaneous Confidence Intervals for Effective Dose Steps in Unbalanced Designs. <i>Biometrical Journal</i> , 2000, 42, 995-1006.	0.6	3
161	Title is missing!. <i>Environmental and Ecological Statistics</i> , 2000, 7, 135-154.	1.9	10
162	The Evaluation of Multiple Clinical Endpoints, with Application to Asthma. <i>Drug Information Journal</i> , 1999, 33, 471-477.	0.5	13

#	ARTICLE	IF	CITATIONS
163	Numerical computation of multivariate t -probabilities with application to power calculation of multiple contrasts. <i>Journal of Statistical Computation and Simulation</i> , 1999, 63, 103-117.	0.7	121
164	Comparison of Methods for the Computation of Multivariate t Probabilities. , 0, .		25
165	Multiple Comparisons Using R. , 0, , .		389
166	Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics. <i>Statistics in Biopharmaceutical Research</i> , 0, , 1-4.	0.6	1